Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tremelimumab - MedImmune

Drug Profile

Tremelimumab - MedImmune

Alternative Names: Anti CTLA 4 monoclonal antibody-Pfizer; CP-675; CP-675206; Ticilimumab

Latest Information Update: 11 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer AIO Studien gGmbH; Amgen; ARCAGY/GINECO Group; AstraZeneca; Azienda Ospedaliera Universitaria Senese; Canadian Cancer Trials Group; Charite - Universitatsmedizin Berlin; Dana-Farber Cancer Institute; Fondazione IRCCS Istituto Nazionale dei Tumori; Grupo Espanol de Tumores Neuroendocrinos; Immunocore; Institute Gustave-Roussy; Kyoto Breast Cancer Research Network; M. D. Anderson Cancer Center; MedImmune; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Pfizer; Seoul National University Hospital; UNICANCER; University College London; University of Maryland Greenbaum Cancer Center; Yonsei University College of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase II Biliary cancer; Bladder cancer; Breast cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastric cancer; Germ cell and embryonal neoplasms; Glioblastoma; Lung cancer; Neuroendocrine tumours; Oropharyngeal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma; Soft tissue sarcoma
  • Phase I/II Colorectal cancer; Malignant melanoma; Oesophageal cancer
  • Phase I Cervical cancer; Diffuse large B cell lymphoma; Gynaecological cancer; Thyroid cancer; Vulvovaginal cancer
  • No development reported Gastrointestinal cancer

Most Recent Events

  • 27 Nov 2018 Grupo Espanol de Tumores Neuroendocrinos plans the DUTHY phase II trial for Thyroid cancer (Combination therapy, Late-stage disease) in Spain , (NCT03753919)
  • 26 Nov 2018 GlaxoSmithKline and Medimmune initiates enrolment in a phase I/II trial for Solid tumors in USA (NCT03693612)
  • 21 Nov 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, France, Netherlands (IV) as at November 2018 (NCT02705482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top